# US 2001/0024814 A1 · Novel beta1-4 n-acetylglucosaminyltransferase and gene encoding

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0024814 A1
- Document ID: US20010024814A1
- Status: Published application
- Kind: A1
- Application number: 09/117,860
- Filed: 1998-08-12
- Published: 2001-09-27
- Earliest claimed: 1996-12-12
- Inventors: SUGURU OGURI; MARI MINOWA; ARUTO YOSHIDA; NAOYUKI TANIGUCHI; MAKOTO TAKEUCHI
- Web page: https://patentgrep.com/patent/US20010024814A1

## CPC

- C12N 9/1051: {Hexosyltransferases (2.4.1)}
- A61P 35/00: Antineoplastic agents
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a novel enzyme having β1→4 N-acetylglucosaminyltransferase (GnT-IV) activity; a gene encoding the enzyme; a recombinant DNA comprising the gene; a host cell comprising the recombinant DNA; a method for producing an enzyme protein having GnT-IV activity comprising culturing the host cell in a medium; and a saccharide in which the sugar chain is modified using a GnT-IV. According to the present invention, a novel GnT-IV, a method for producing the enzyme and a gene coding for the enzyme are provided. With the GnT-IV of the present invention, it has become possible to produce a saccharide having a branching structure which could not be formed with conventional glycosyltransferases. Thus, the GnT-IV of the invention is useful not only for producing or improving glycoconjugate type pharmaceuticals, reagents and foods, but also for modifying the sugar chain structure of any biopolymer.

## Claims

### Claim 1

A β1→4 N-acetylglucosaminyltransferase having an activity to produce a saccharide having a partial structure represented by the formula below: 23
using UDP-GlcNAc as a sugar donor and a saccharide having a partial structure represented by the formula below as a sugar receptor: 24

### Claim 2 (depends on 1)

The β1→4 N-acetylglucosaminyltransferase of claim 1, wherein the saccharide as a sugar receptor is an oligosaccharide, polysaccharide, glycoconjugate (glycopeptide, glycoprotein, glycolipid or proteoglycan) or a derivative thereof.

### Claim 3 (depends on 1)

The β1→4 N-acetylglucosaminyltransferase of claim 1, wherein the sugar receptor is a saccharide having the partial structure represented by the formula below: 25
wherein R1: H—, Manα1→6 or GlcNAcβ1→6
R2: H—, Manα1→3 or GlcNAcβ1→2
R3: —OH or β1→4GlcNAc→R4
R4: —OH, —H, -pyridylamine or -peptide chain.

### Claim 4

A β1→4 N-acetylglucosaminyltransferase comprising the amino acid sequences shown in SEQ ID NOS: 1-14 as partial sequences.

### Claim 5

A β1→4 N-acetylglucosaminyltransferase consisting of the amino acid sequence shown in SEQ ID NO: 18 or the amino acid sequence shown in SEQ ID NO: 18 which has addition, deletion or substitution of one or more amino acid residues and yet which produces β1→4 N-acetylglucosaminyltransferase activity.

### Claim 6

A β1→4 N-acetylglucosaminyltransferase consisting of a partial sequence of the amino acid sequence shown in SEQ ID NO: 18 including at least from position 93 to position 383 residues, or said partial sequence which has addition, deletion or substitution of one or more amino acid residues and yet which produces β1→4 N-acetylglucosaminyltransferase activity.

### Claim 7

A β1→4 N-acetylglucosaminyltransferase consisting of the amino acid sequence shown in SEQ ID NO: 24 or the amino acid sequence shown in SEQ ID NO: 24 which has addition, deletion or substitution of one or more amino acid residues and yet which produces β1→4 N-acetylglucosaminyltransferase activity.

### Claim 8

A β1→4 N-acetylglucosaminyltransferase consisting of a partial sequence of the amino acid sequence shown in SEQ ID NO: 24 including at least from position 94 to position 383 residues, or said partial sequence which has addition, deletion or substitution of one or more amino acid residues and yet which produces β1→4 N-acetylglucosaminyltransferase activity.

### Claim 9

A β1→4 N-acetylglucosaminyltransferase consisting of the amino acid sequence shown in SEQ ID NO: 37 or the amino acid sequence shown in SEQ ID NO: 37 which has addition, deletion or substitution of one or more amino acid residues and yet which produces β1→4 N-acetylglucosaminyltransferase activity.

### Claim 10

A β1→4 N-acetylglucosaminyltransferase consisting of a partial sequence of the amino acid sequence shown in SEQ ID NO: 37 including at least from position 91 to position 390 residues, or said partial sequence which has addition, deletion or substitution of one or more amino acid residues and yet which produces β1→4 N-acetylglucosaminyltransferase activity.

### Claim 11 (depends on 5, 6)

A β1→4 N-acetylglucosaminyltransferase gene coding for the β1→4 N-acetylglucosaminyltransferase of claim 5 or 6.

### Claim 12 (depends on 7, 8)

A β1→4 N-acetylglucosaminyltransferase gene coding for the β1→4 N-acetylglucosaminyltransferase of claim 7 or 8.

### Claim 13 (depends on 9, 10)

A β1→4 N-acetylglucosaminyltransferase gene coding for the β1→4 N-acetylglucosaminyltransferase of claim 9 or 10.

### Claim 14

A β1→4 N-acetylglucosaminyltransferase gene consisting of the nucleotide sequence shown in SEQ ID NO: 17.

### Claim 15

A β1→4 N-acetylglucosaminyltransferase gene consisting of the nucleotide sequence shown in SEQ ID NO: 23.

### Claim 16

A β1→4 N-acetylglucosaminyltransferase gene consisting of the nucleotide sequence shown in SEQ ID NO: 36.

### Claim 17 (depends on 11, 12, 13, 14, 15, 16)

A recombinant DNA obtained by inserting into a vector DNA the β1→4 N-acetylglucosaminyltransferase gene of any one of claims 11 to 16.

### Claim 18 (depends on 11, 12, 13, 14, 15, 16)

A chromosomal fragment comprising a part or all of the β1→4 N-acetylglucosaminyltransferase gene of any one of claims 11 to 16.

### Claim 19 (depends on 17)

A host cell carrying the recombinant DNA of claim 17.

### Claim 20 (depends on 18)

A host cell into which the chromosomal fragment of claim 18 is artificially introduced.

### Claim 21 (depends on 1, 2, 3)

A method for purifying the β1→4 N-acetylglucosaminyltransferase of any one of claims 1 to 3 from biological samples.

### Claim 22 (depends on 19)

A method for producing a β1→4 N-acetylglucosaminyltransferase comprising culturing the host cell of claim 19 in a medium and recovering the β1→4 N-acetylglucosaminyltransferase from the resultant culture.

### Claim 23 (depends on 20)

A method for producing a β1→4 N-acetylglucosaminyltransferase comprising culturing the host cell of claim 20 in a medium and recovering the β1→4 N-acetylglucosaminyltransferase from the resultant culture.

### Claim 24 (depends on 19)

A method for producing a β1→4 N-acetylglucosaminyltransferase comprising recovering the β1→4 N-acetylglucosaminyltransferase from the secreta, body fluid or homogenate originated from the host cell of claim 19.

### Claim 25 (depends on 20)

A method for producing a β1→4 N-acetylglucosaminyltransferase comprising recovering the β1→4 N-acetylglucosaminyltransferase from the secreta, body fluid or homogenate originated from the host cell of claim 20.

### Claim 26 (depends on 1, 2, 3)

A saccharide of which the sugar chain structure is modified with the β1→4 N-acetylglucosaminyltransferase of any one of claims 1 to 3.

### Claim 27 (depends on 26)

The saccharide of claim 26, which is an oligosaccharide, a glycopeptide, a glycoprotein or a derivative thereof.

### Claim 28 (depends on 11, 12, 13, 14, 15, 16)

A method for modifying a branching structure of a sugar chain of a glycoprotein produced by a host cell, comprising introducing into the host cell the β1→4 N-acetylglucosaminyltransferase gene of any one of claims 11 to 16.

### Claim 29 (depends on 28)

A glycoprotein in which a branching structure of a sugar chain is modified by the method of claim 28.

### Claim 30 (depends on 29)

The glycoprotein of claim 29, which is erythropoietin.
